Hyderabad based CDMO company that offers services to leading global pharmaceutical and fine chemical majors in their NCE development endeavours. From process research & development to late-stage clinical and commercial manufacturing we are committed to provide customers with products fulfilling customer needs and expectations.
Financial Results:
Suven Pharmaceuticals Ltd reported Revenues for Q4FY24 of ₹253.00 Crores down from ₹369.00 Crore year on year, a fall of 31.44%.
Total Expenses for Q4FY24 of ₹199.00 Crores down from ₹215.00 Crores year on year, a fall of 7.44%.
Consolidated Net Profit of ₹53.00 Crores down 57.26% from ₹124.00 Crores in the same quarter of the previous year.
The Earnings per Share is ₹2.10, down 56.88% from ₹4.87 in the same quarter of the previous year.
*It is important to note that the way the results have been accounted for are slightly different than the ones the companies may choose to publish.
*The presented data is automatically generated. It may occasionally generate incorrect information.